Dec 23 (Reuters) - Helix Biopharma Corp HBP.TO :
* Under terms of agreement, Xisle has paid an up-front fee and agreed to subsequent milestone payments
* Helix Biopharma Corp - Xisle will be responsible for continued clinical development and subsequent commercialization of product
* Helix Biopharma Corp successfully out-licenses late stage Biphasix technology
* Helix Biopharma Corp - signed exclusive out-license agreement with Xisle Pharma ventures trust for company's late-stage, Biphasix technology platform Source text for Eikon: ID:nMKWSQ5j9a Further company coverage: HBP.TO